DOCSLIB.ORG

Downloaded for Personal Use Only

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Downloaded for Personal Use Only Original Article 263 Pharmacokinetics, Safety and Tolerability of Trifl usal and its Main Active Metabolite HTB in Healthy Chinese Subjects Authors M. Wang , Q. Zhang , M. Huang , S. Zong , W. Hua , W. Zhou Affi liation Clinical Pharmacology Laboratory, The Second Affi liated Hospital of Soochow University, Suzhou, China Key words Abstract rapidly absorbed with a mean Tmax of 0.55–0.92 h ● ▶ trifl usal ▼ and a mean t1/2 kel of 0.35–0.65 h, HTB was ● ▶ pharmacokinetics Objective: T r i fl usal presents comparable absorbed with a mean Tmax of 2.35–3.03 h and a ● ▶ antiplatelet activity antiplatelet activity to aspirin while presenting a mean t of 52.5–65.57 h. C and AUC for tri- ● ▶ safety 1/2 kel max more favourable safety profi le, and is used in the fl usal and HTB were approximately dose propor- treatment of thrombosis. The study aimed to tional over the 300–900 mg dose range. In the evaluate the pharmacokinetics and safety of trif- steady state, the accumulation index (R) indi- lusal and its major metabolite 2-(hydroxyl)-4- cated that the exposure of trifl usal increased (trifl uoromethyl)- benzoic acid (HTB) in healthy slightly with repeated dosing, and the exposure Chinese subjects. of HTB increased obviously. 3 adverse events cer- Methods: 30 healthy subjects were recruited in tainly related to the investigational drugs this randomized, single-center, and open-label, occurred in the multiple-dose phase. parallel, single ascending doses (300, 600, Conclusion: Following oral dosing under fast- 900 mg) and multiple doses (600 mg, once daily ing condition, trifl usal is promptly absorbed and for 7 days) study. Plasma samples were analyzed rapidly depleted from the systemic circulation. with a validated liquid chromatography tandem HTB is quickly generated from trifl usal and mass spectrometry (LC/MS/MS) method. Safety slowly eliminated. Trifl usal accumulates slightly was assessed by adverse events, ECG, laboratory in the body. HTB plasma concentration builds up testing, and vital signs. progressively toward steady-state. received 06 . 08 . 2013 Results: T r i fl usal was safe and well tolerated. accepted 13 . 09 . 2013 After single-dose administration, trifl usal was Bibliography DOI http://dx.doi.org/ Introduction trifl usal is deacetylated in the liver to HTB as the 10.1055/s-0033-1357180 Published online: ▼ main active metabolite. And unchanged trifl usal October 8, 2013 T r i fl usal (2-acetoxy-4-trifl uoromethyl benzoic and HTB are eliminated primarily through the Drug Res 2014; acid; CAS 322-79-2) is a new molecule related to kidneys [ 5 ] . Unchanged trifl usal, HTB and HTB This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. 64: 263–268 salicylic acid which is used in the prevention and glycine conjugate have been identifi ed in the © Georg Thieme Verlag KG treatment of thromboembolic disease [ 1 , 2 ] . Trif- urine. Trifl usal has 2 major pharmacological Stuttgart · New York lusal inhibits cycloxygenase-1 in platelets, but eff ects: in platelets it inhibits activation of ISSN 2194-9379 seems to leave intact the arachidonic acid meta- thrombogenic mechanisms, while in the nervous bolic pathway in endothelial cells. Trifusal and system it blocks the main biochemical pathways Correspondence Q. Zhang HTB stimulate the constitutive activity of NO that lead to cell damage during ischemia [ 3 ] . Chief Pharmacist synthase (cNOS) and consequently increase NO Following oral dosing, trifl usal is promptly Clinical Pharmacology Laboratory production by endothelial cells and leucocytes. absorbed and rapidly depleted from the systemic The Second Affi liated Hospital Trifl usal presents comparable antiplatelet activ- circulation. Its concentration was measurable of Soochow University ity to aspirin while presenting a more favourable only up to 4 h after administration [ 2 ] . Main NO.1055 Sanxiang Road safety profi le [ 3 ] . pharmacokinetic parameters of trifl usal and HTB 215004 Suzhou T r i fl usal is absorbed in the small intestine and its in healthy subjects of literature data [ 1 , 6 , 7 ] are China ▶ Tel.: + 86/512/67783 687 bioavailability ranges from 83 to 100 % [ 1 , 4 ] . It summarized in ● Table 1 . The pharmacokinetic Fax: + 86/512/67783 686 binds to plasma proteins almost entirely (99 %) profi les of trifl usal or HTB do not appear to have [email protected] and crosses organic barriers readily. In humans, clinically signifi cant diff erences in elderly or Wang M et al. Trifl usal and HTB PK in Chinese Subjects … Drug Res 2014; 64: 263–268 264 Original Article Study population Table 1 Pharmacokinetics of trifl usal and HTB in healthy subjects from literature data. Chinese healthy volunteers, aged 18–40 years, male and female (nonpregnant and nonlactating), weighing not less than 50 kg, PK parameters a 300 mg [6] 600 mg [7] 900 mg [1] body mass index (BMI) between 19 and 24 kg/m2 , were enrolled. (n = 9) (n = 24) (n = 8) Subjects were all in good health as determined by their past Trifl usal medical history, physical examination, vital signs, standard lab- C max (μg/mL) – 14.48 ± 7.22 11.61 ± 1.68 oratory parameters (e. g. haematology, blood chemistry and uri- b T max (h) – 0.875 (0.25–1.5) 0.88 ± 0.26 nalysis), and 12-lead ECG within 2 weeks before the fi rst dosing tl/2 kel (h) 0.64 ± 0.08 0.76 ± 0.64 0.53 ± 0.12 of the study medication. Female subjects were required to have AUC0–t (μg/mL · h) 3.0 ± 0.5 16.22 ± 7.58 – a negative pregnancy test at screening and to agree on using an HTB eff ective contraception method during the study period. C (μg/mL) – 65.51 ± 19.44 92.71 ± 17.14 max The persons are excluded out of the study who are: infected of T (h) – 2 (0.75–12) b 4.96 ± 1.37 max hepatitis B or C virus or HIV or Syphilis; pregnant or breastfeed- tl/2 kel (h) 59.7 ± 11.3 43.13 ± 6.56 34.29 ± 5.32 ing; having a history of or having pulmonary, cardiovascular, AUC0–t (μg/mL · h) 1321 ± 304 2877.97 ± 881.24 - a Data were presented as mean ± SD neurological, psychiatric, endocrine or coagulation disorders, b Median (range) having renal or hepatic disease or any physical attributes that may infl uence the trial results; medicated or using drugs of any younger volunteers [ 3 , 8 ] . No plasma accumulation of the parent kind in ≤ 2 weeks before the study commencement; having a his- compound was noticed in volunteers > 80 years old who received tory of or currently abusing of drugs or alcohol; smoking of trifl usal 300 mg × 2/day for 13 days [ 9 ] . Additionally, the steady- more than 5 cigarettes per day or equivalent; participating in state level of HTB is reached within 8–10 days of treatment another drug study or donation of blood in ≤ 90 days prior to the [ 10 , 11 ] . study. At present, no available data on pharmacokinetics of trifl usal and HTB in Chinese subjects are reported. The objective of this Study design study was to evaluate the pharmacokinetic profi les of trifl usal This was a randomized, single-center, open-label study in which and HTB after oral single doses (300, 600, 900 mg) and multiple 30 healthy subjects of either sex were randomly assigned to doses (600 mg, once daily for 7 days) of trifl usal capsules in group 1, group 2, and group 3 (5 females and 5 males in each healthy Chinese subjects. Moreover, the safety and tolerability of group). The subjects were hospitalized at 7:00 pm the night trifl usal in Chinese subjects were also assessed. before dosing and required to fast overnight (10 h). Throughout the sequential single-dose and multiple-dose trials, trifl usal was administrated in fasting state. After the trial, the subjects were Subjects and Methods released and visited the clinic for post-test of vital signs, 12-lead ▼ ECG, physical examination, and routine laboratory test. If the Study approval principal investigator determined that a subject required addi- The clinical trial was licensed in State Food and Drug Adminis- tional tests, the subject obeyed these orders. tration in China with the registration number of 2010L01996. The study was performed at the Second Affi liated Hospital of Single dose administration Soochow University in Suzhou, China. The study was conducted The therapeutic dose of trifl usal capsule was 300 mg, 600 mg or in accordance with the principles of the Declaration of Helsinki 900 mg once daily. On day 1, subjects of group 1, group 2, and [ 12 ] and Good Clinical Practice (GCP) in China [ 13 ] , and the pro- group 3 received a single oral administration of 300 mg, 600 mg, tocol was approved by the Independent Ethics Committee of the and 900 mg of trifl usal capsules, respectively. Study medication hospital with the approval number of 2013 (12). All study par- was administered at 7:00 am with 250 mL of water. Water intake ticipants gave written informed consent before the conduct of was prohibited within the following 2 h after drug administration the study-related procedures. and a standard lunch was served 4 h after dosing. Blood samples (4 mL each) were collected from vein vessels in the antebrachium predose (0 h) and 10, 20, 30 and 45 min, and 1, 1.25, 1.5, 2, 2.5, 3, Materials and reagents This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. T r i fl usal reference standard (purity of 99.7 %) and HTB reference 3.5, 4, 6, 8, 12, 24, 48, 72, 120 and 168 h after dosing.
Load more

Recommended publications
  • Stroke Prevention in Chronic Kidney Disease Disclosures
    5/18/2020 Controversies: Stroke Prevention in Chronic Kidney Disease Wei Ling Lau, MD FASN FAHA FACP Assistant Professor, Nephrology University of California, Irvine Visiting Fellow at OptumLabsCOPY Disclosures • Prior or current research funding from NIH, AHA, Sanofi, ZS Pharma, and Hub Therapeutics. • Associate Medical Director for home peritoneal dialysis at Fresenius University Dialysis Center of Orange. • Has beenNOT on Fresenius medical advisory board for Velphoro. • No conflicts of interest relevant to the current talk. Controversies: Stroke prevention in CKD Wei Ling Lau, MD DO 1 5/18/2020 Stroke Prevention in CKD • Blood pressure targets • Antiplatelet agents • Statins • Anticoagulation Controversies: Stroke prevention in CKD Wei Ling Lau, MD COPY BP TARGETS Data is limited, as patients with CKD were historically excluded from clinical trials NOT Whelton 2017 ACC/AHA hypertension guidelines [Hypertension 2018] Controversies: Stroke prevention in CKD Wei Ling Lau, MD DO 2 5/18/2020 Systolic Blood Pressure Intervention Trial SPRINT: BP lowering to <120 vs <140 mmHg significantly lowered rate of CVD composite primary outcome; no clear effect on stroke Controversies: Stroke prevention in CKD The SPRINT Research Group. N Engl J Med 2015 p2103 Wei Ling Lau, MD COPY SPRINT subgroup analysis: CKD • Patients with CKD stage 3‐4 (eGFR of 20 to <60) comprised 28% of the SPRINT study population • Intensive BP management seemed to provide the same benefits for reduction in the CVD composite primary outcomeNOT – but did not impact stroke Controversies: Stroke prevention in CKD Cheung 2017 J Am Soc Nephrol p2812 Wei Ling Lau, MD DO 3 5/18/2020 The hazard of incident stroke associated with systolic BP (SBP) and chronic kidney disease (CKD)BP using and an unadjusted stroke model risk: that contained J‐shaped dummy variables association for CKD and BP groups (A) and a fully adjusted model that contained dummy variables for CKD and BP grou..
    [Show full text]
  • Toward an in Vitro Bioequivalence Test
    TOWARD AN IN VITRO BIOEQUIVALENCE TEST by Jie Sheng A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Pharmaceutical Sciences) In The University of Michigan 2007 Doctoral Committee: Professor Gordon L. Amidon, Chair Professor Henry Y. Wang Associate Professor Nair Rodriguez-Hornedo Associate Professor Steven P. Schwendeman Jie Sheng © 2007 All Rights Reserved To Kurt Q. Zhu, my husband and my very best friend, and to Diana S. Zhu and Brandon D. Zhu, my lovely children. ii Acknowledgements Most of all, I thank Prof. Gordon L. Amidon, for his support, guidance, and inspiration during my graduate studies at the University of Michigan. Being his student is the best step happened in my career. I am always amazed by his vision, energy, patience and dedication to the research and his students. He trained me to grow as a scientist and as a person. I also wish to thank all of my committee members, Professors David Fleisher, Nair Rodriguez-Hornedo, Steven Schwendeman and Henry Wang, for their very insightful and constructive suggestions to my research. It took all their efforts to raise me as a professional scientist in pharmaceutical field. They all contributed significantly to development and improvement of my graduate work. Especially, Prof. Wang has also guided me in thinking of career development as if 20-year later. I felt to be his student in many ways. I thank mentors, colleagues and friends, Prof. John Yu from Ohio State University, Paul Sirois from Eli Lilly, Kurt Seefeldt, Chet Provoda, Jonathan Miller, John Chung, Chris Landoswki, Haili Ping and Yasuhiro Tsume from College of Pharmacy, for many interesting discussions throughout the graduate program.
    [Show full text]
  • CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene and Pathophysiological Conditions
    Review CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene and Pathophysiological Conditions Rossana Roncato 1,*,†, Jacopo Angelini 2,†, Arianna Pani 2,3,†, Erika Cecchin 1, Andrea Sartore-Bianchi 2,4, Salvatore Siena 2,4, Elena De Mattia 1, Francesco Scaglione 2,3,‡ and Giuseppe Toffoli 1,‡ 1 1 Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico (CRO), IRCCS, 33081 Aviano, Italy; [email protected] (E.C.); [email protected] (E.D.M.); [email protected] (G.T.) 2 Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, 20122 Milan, Italy; [email protected] (J.A.); [email protected] (A.P.); [email protected] (A.S-B.); [email protected] (S.S.); [email protected] (F.S.) 3 Clinical Pharmacology Unit, ASST Grande Ospedale Metropolitano Niguarda, Piazza dell'Ospedale Maggiore 3, 20162 Milan, Italy 4 Department of Hematology and Oncology, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy * Correspondence: [email protected]; Tel.:+390434659130 † These authors contributed equally. ‡ These authors share senior authorship. Int. J. Mol. Sci. 2020, 21, x; doi: www.mdpi.com/journal/ijms Int. J. Mol. Sci. 2020, 21, x 2 of 8 Table S1. Co-administered agents categorized according to their potential risk for Drug-Drug interaction (DDI) in combination with CDK4/6 inhibitors (CDKis). Colors suggest the risk of DDI with CDKis: green, low risk DDI; orange, moderate risk DDI; red, high risk DDI. ADME, absorption, distribution, metabolism, and excretion; GI, Gastrointestinal; TdP, Torsades de Pointes; NTI, narrow therapeutic index. * Cardiological toxicity should be considered especially for ribociclib due to the QT prolongation.
    [Show full text]
  • Salts of Menantine and Cox-Inhibitors and Their Crystal Form in The
    (19) & (11) EP 2 098 500 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 09.09.2009 Bulletin 2009/37 C07C 57/40 (2006.01) C07C 63/70 (2006.01) C07C 65/01 (2006.01) C07C 211/38 (2006.01) (2006.01) (2006.01) (21) Application number: 08384002.5 A61K 31/13 A61K 31/192 A61P 25/02 (2006.01) A61P 29/00 (2006.01) (2006.01) (22) Date of filing: 07.03.2008 A61P 25/28 (84) Designated Contracting States: • Tesson, Nicolas AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 08028 Barcelona (ES) HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT • Farran, Joan RO SE SI SK TR 08028 Barcelona (ES) Designated Extension States: • Rafecas, Llorenc AL BA MK RS 08028 Barcelona (ES) (71) Applicant: Laboratorios Del. Dr. Esteve, S.A. (74) Representative: Peters, Hajo et al 08041 Barcelona (ES) Graf von Stosch Patentanwaltsgesellschaft mbH (72) Inventors: Prinzregentenstrasse 22 • Buschmann, Helmut, Heinrich, Dr. 80538 München (DE) 52076 Aachen (Walheim) (DE) (54) Salts of menantine and cox-inhibitors and their crystal form in the treatment of pain (57) The present invention relates to salts of Memantine and COX-INHIBITORs, their crystal form, the processes for preparation of the same and their uses as medicaments, more particularly for the treatment of pain. EP 2 098 500 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 098 500 A1 Description [0001] The present invention relates to salts of Memantine and COX-INHIBITORs, their crystal from, and their specific polymorphs, the processes for preparation of the same and their uses as medicaments, more particularly for the treatment 5 of pain.
    [Show full text]
  • Antithrombotic Treatment After Stroke Due to Intracerebral Haemorrhage (Review)
    Cochrane Database of Systematic Reviews Antithrombotic treatment after stroke due to intracerebral haemorrhage (Review) Perry LA, Berge E, Bowditch J, Forfang E, Rønning OM, Hankey GJ, Villanueva E, Al-Shahi Salman R Perry LA, Berge E, Bowditch J, Forfang E, Rønning OM, Hankey GJ, Villanueva E, Al-Shahi Salman R. Antithrombotic treatment after stroke due to intracerebral haemorrhage. Cochrane Database of Systematic Reviews 2017, Issue 5. Art. No.: CD012144. DOI: 10.1002/14651858.CD012144.pub2. www.cochranelibrary.com Antithrombotic treatment after stroke due to intracerebral haemorrhage (Review) Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 3 BACKGROUND .................................... 5 OBJECTIVES ..................................... 5 METHODS ...................................... 6 RESULTS....................................... 8 Figure1. ..................................... 9 Figure2. ..................................... 11 Figure3. ..................................... 12 DISCUSSION ..................................... 14 AUTHORS’CONCLUSIONS . 15 ACKNOWLEDGEMENTS . 15 REFERENCES ..................................... 15 CHARACTERISTICSOFSTUDIES . 18 DATAANDANALYSES. 31 Analysis 1.2. Comparison 1 Short-term antithrombotic treatment, Outcome 2 Death. 31 Analysis 1.6. Comparison 1 Short-term antithrombotic
    [Show full text]
  • Antiplatelet Regimens in the Long-Term Secondary Prevention of Transient Ischaemic Attack and Ischaemic Stroke: an Updated Network Meta-Analysis
    Open Access Research BMJ Open: first published as 10.1136/bmjopen-2015-009013 on 17 March 2016. Downloaded from Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis Peng-Peng Niu, Zhen-Ni Guo, Hang Jin, Ying-Qi Xing, Yi Yang To cite: Niu P-P, Guo Z-N, ABSTRACT et al Strengths and limitations of this study Jin H, . Antiplatelet Objective: To examine the comparative efficacy and regimens in the long-term safety of different antiplatelet regimens in patients with ▪ secondary prevention of Since the dose of aspirin ranged from 30 to prior non-cardioembolic ischaemic stroke or transient transient ischaemic attack 1500 mg daily, treatment with aspirin was and ischaemic stroke: an ischaemic attack. divided into four different regimens and treat- updated network meta- Design: Systematic review and network meta-analysis. ment with aspirin plus dipyridamole was divided analysis. BMJ Open 2016;6: Data sources: As on 31 March 2015, all randomised into two different regimens. e009013. doi:10.1136/ controlled trials that investigated the effects of ▪ Duration of follow-up was included in the model bmjopen-2015-009013 antiplatelet agents in the long-term (≥3 months) to perform the network meta-analysis. secondary prevention of non-cardioembolic transient ▪ Estimates from sensitivity analyses were compat- ▸ Prepublication history and ischaemic attack or ischaemic stroke were searched ible with the main analysis, except that cilostazol additional material is and identified. was not significantly more effective than clopido- available. To view please visit Outcome measures: The primary outcome measure grel and triflusal in preventing serious vascular the journal (http://dx.doi.org/ of efficacy was serious vascular events (non-fatal events when setting the prior on the variance 10.1136/bmjopen-2015- stroke, non-fatal myocardial infarction and vascular equal to a uniform (0, 1000).
    [Show full text]
  • Digital Ischemic Events Related to Gemcitabine: Report of Two Cases and a Systematic Review
    257 case report Digital ischemic events related to gemcitabine: Report of two cases and a systematic review Cvetka Grasic Kuhar, Tanja Mesti, Branko Zakotnik Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia Received 1 February 2010 Accepted 1 March 2010 Correspondence to: Cvetka Grasič Kuhar, MD. PhD, Department of Medical Oncology, Institute of Oncology Ljubljana, Zaloška c. 2, SI-1000 Ljubljana, Slovenia; Phone: +386 1 5879282; Fax: +386 1 5879305; E-mail: [email protected] Disclosure: No potential conflicts of interest were disclosed. Background. Gemcitabine is a potent cytotoxic agent used in the treatment of many solid tumours, sarcomas and lymphomas. Vascular toxicity and thrombotic events related to gemcitabine seem to be underreported. Case report. We report two cases of gemcitabine related digital ischemic events. Case 1. A 65-year-old man was given the first-line treatment with gemcitabine for the advanced adenocarcinoma of pancreas. After four weekly doses of gemcitabine (total dose 4000 mg/m2) he presented with Raynaud’s like phenom- enon and ischemic fingertips necrosis in five digits of both hands. Symptoms resolved in all but one digit after stopping chemotherapy and treatment with iloprost trometamol infusion. Case 2. A 77-year-old man, ex-smoker, was administered a combination of gemcitabine and cisplatin as the first-line treatment for the locally advanced bladder cancer. After 4 cycles of the treatment (total dose of gemcitabine 4000 mg/m2) the patient suffered digital ischemia and necrosis on two digits of a right leg. Arteriography revealed preex- isting peripheral arterial occlusive disease (PAOD) of both legs with very good peripheral collateral circulation and absent microcirculation of affected two digits.
    [Show full text]
  • Study Protocol
    Protocol 3-001 Confidential 28APRIL2017 Version 4.1 Asahi Kasei Pharma America Corporation Synopsis Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects with Severe Sepsis and Coagulopathy Name of Sponsor/Company: Asahi Kasei Pharma America Corporation Name of Investigational Product: ART-123 Name of Active Ingredient: thrombomodulin alpha Objectives Primary: x To evaluate whether ART-123, when administered to subjects with bacterial infection complicated by at least one organ dysfunction and coagulopathy, can reduce mortality. x To evaluate the safety of ART-123 in this population. Secondary: x Assessment of the efficacy of ART-123 in resolution of organ dysfunction in this population. x Assessment of anti-drug antibody development in subjects with coagulopathy due to bacterial infection treated with ART-123. Study Center(s): Phase of Development: Global study, up to 350 study centers Phase 3 Study Period: Estimated time of first subject enrollment: 3Q 2012 Estimated time of last subject enrollment: 3Q 2018 Number of Subjects (planned): Approximately 800 randomized subjects. Page 2 of 116 Protocol 3-001 Confidential 28APRIL2017 Version 4.1 Asahi Kasei Pharma America Corporation Diagnosis and Main Criteria for Inclusion of Study Subjects: This study targets critically ill subjects with severe sepsis requiring the level of care that is normally associated with treatment in an intensive care unit (ICU) setting. The inclusion criteria for organ dysfunction and coagulopathy must be met within a 24 hour period. 1. Subjects must be receiving treatment in an ICU or in an acute care setting (e.g., Emergency Room, Recovery Room).
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • Use of Antiplatelet Agents Decreases the Positive Predictive Value of Fecal Immunochemical Tests for Colorectal Cancer but Does Not Affect Their Sensitivity
    Journal of Personalized Medicine Article Use of Antiplatelet Agents Decreases the Positive Predictive Value of Fecal Immunochemical Tests for Colorectal Cancer but Does Not Affect Their Sensitivity Yoonsuk Jung 1,† , Eui Im 2,†, Jinhee Lee 3, Hyeah Lee 4 and Changmo Moon 5,6,* 1 Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 03181, Korea; [email protected] 2 Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine and Cardiovascular Center, Yongin Severance Hospital, Yongin 16995, Korea; [email protected] 3 Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon 16499, Korea; [email protected] 4 Clinical Trial Center, Ewha Womans University Mokdong Hospital, Seoul 07985, Korea; [email protected] 5 Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul 07985, Korea 6 Inflammation-Cancer Microenvironment Research Center, Ewha Womans University, Seoul 07804, Korea * Correspondence: [email protected]; Tel.: +82-2-2650-2945; Fax: +82-2-2650-5936 † These authors contributed equally to this study. Abstract: Previous studies have evaluated the effects of antithrombotic agents on the performance of fecal immunochemical tests (FITs) for the detection of colorectal cancer (CRC), but the results were inconsistent and based on small sample sizes. We studied this topic using a large-scale population- based database. Using the Korean National Cancer Screening Program Database, we compared Citation: Jung, Y.; Im, E.; Lee, J.; Lee, the performance of FITs for CRC detection between users and non-users of antiplatelet agents and H.; Moon, C. Use of Antiplatelet warfarin.
    [Show full text]
  • Effect of Argatroban on Microthrombi Formation and Brain Damage in the Rat Middle Cerebral Artery Thrombosis Model
    Effect of Argatroban on Microthrombi Formation and Brain Damage in the Rat Middle Cerebral Artery Thrombosis Model Hiroshi Kawai#, Kazuo Umemura and Mitsuyoshi Nakashima Department of Pharmacology, Hamamatsu University School of Medicine, 3600 Handa-cho, Hamamatsu 431-31, Japan Received May 19, 1995 Accepted July 26, 1995 ABSTRACT-Ischemic cerebral infarcts induce hypercoagulation and microthrombosis in the surrounding region, thus leading to vascular occlusion. We determined whether microthrombi contribute to the spread- ing of ischemic lesions following thrombotic middle cerebral artery (MCA) occlusion and also determined whether argatroban, a selective thrombin inhibitor, reduces the formation of the microthrombi and the area of the ischemic lesions. The rat left MCA was occluded by a platelet-rich thrombus formed following the photochemical reaction between rose bengal and green light. Microthrombi were histologically identified in the left hemisphere. The extent of ischemic lesions and microthrombi containing fibrin increased in a time- dependent manner after MCA occlusion. Argatroban inhibited the formation of microthrombi up to 3 hr after MCA occlusion; beyond 3 hr, it was ineffective. Argatroban also significantly (P<0.01) reduced the size of ischemic cerebral lesions at 6 hr after MCA occlusion. It is concluded that the formation of microthrombi contributes to the progression of ischemic lesions in the early stage. It is likely that thrombin generated following thrombotic MCA occlusion contributes to the progression of ischemic lesions by promoting the formation of microthrombi. Argatroban can reduce the formation of microthrombi and ischemic lesions in the early stage. Keywords: Thrombin, Argatroban, Microthrombosis, Thrombotic middle cerebral artery occlusion The progression of focal cerebral infarction is depend- in the ischemic areas and might contribute to micro- ent on numerous factors (1, 2).
    [Show full text]